CLINICAL_TRIALS
trial_result
· 2024-03-08
Clinical Trial Update: Safety and Tolerability of BI 409306 in Patients With Schizophrenia [Phase 1]
Summary
This Phase 1 trial assessed the safety and tolerability of BI 409306 in patients with schizophrenia. Results have been posted following study completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2024-03-08